Priority Review for Cinryze was granted for all three requested indications, prevention, pre-procedure prevention, and acute treatment of attacks of Hereditary Angioedema (HAE).
Priority Review will allow for an expedited review of critical new drugs faster than standard review. Health Canada is expected to complete its review in the second half of 2012.
HAE is a debilitating and potentially life-threatening genetic disorder. It is a variable disease and occurs due to a deficiency of C1 inhibitor, a human plasma protein that prevents swelling.
ViroPharma chief operating officer Daniel Soland said they will submit the NDS to Health Canada before the end of the quarter, and look forward to a Canadian regulatory decision.
"The receipt of priority review status from Health Canada marks another important milestone in our efforts to make Cinryze available around the globe to people living with HAE," Soland added.